Demand for weight-loss treatments opens new markets for Tasmania’s poppy industry

A shortage of the weight-loss drug Ozempic to treat type 2 diabetes has opened up new markets for the Tasmanian alkaloid poppy sector.

It’s the shot in the arm northern Tasmanian pharmaceutical business Extractas Bioscience needed.

For nearly a decade the poppy processor has struggled with a…